Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

  • Anders Waage
  • Peter Gimsing
  • Peter Fayers
  • Niels Abildgaard
  • Lucia Ahlberg
  • Bo Bjorkstrand
  • Kristina Carlson
  • Inger Marie Dahl
  • Karin Forsberg
  • Nina Gulbrandsen
  • Einar Haukas
  • Oyvind Hjertner
  • Martin Hjorth
  • Torbjorn Karlsson
  • Lene Meldgaard Knudsen
  • Johan Lanng Nielsen
  • Olle Linder
  • Ulf-Henrik Mellqvist
  • Ingerid Nesthus
  • Jurgen Rolke
  • Maria Strandberg
  • Jon Hjalmar Sorbo
  • Finn Wisloff
  • Gunnar Juliusson
  • Ingemar Turesson
Publiceringsår: 2010
Språk: Engelska
Sidor: 1405-1412
Publikation/Tidskrift/Serie: Blood
Volym: 116
Nummer: 9
Dokumenttyp: Artikel i tidskrift
Förlag: American Society of Hematology


In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P < .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, non-neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at as #NCT00218855. (Blood. 2010;116(9):1405-1412)


  • Hematology


  • ISSN: 1528-0020

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen